Tribute Pharmaceuticals Canada Inc (TBUFF) 0.8600
Post# of 273330
Posted On: 10/11/2015 6:45:23 AM
Tribute Pharmaceuticals Canada Inc (TBUFF) 0.8600 $TBUFF
Tribute Comments on Trading Activity at the Request of IIROC
Marketwired - Tue Sep 29, 2:17PM CDT
Tribute Pharmaceuticals Canada Inc. (TSX VENTURE: TRX)(OTCQX: TBUFF) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced at the request of the Investment Industry Regulatory Organization of Canada ("IIROC", that it is not aware of any reason for the recent decrease in the Company's share price.
TRX.VN: 1.120 (-0.030), POZN: 6.29 (+0.10)
Tribute Pharmaceuticals posts 2Q loss
Automated Insights - Mon Aug 17, 8:13AM CDT
MILTON, Ontario (AP) _ Tribute Pharmaceuticals Canada Inc. (TBUFF) on Monday reported a loss of $7.2 million in its second quarter.
Tribute Pharmaceuticals Announces Second Quarter 2015 Results
Marketwired - Mon Aug 17, 7:31AM CDT
Tribute Pharmaceuticals Canada Inc. (TSX VENTURE: TRX)(OTCQX: TBUFF) ("Tribute" or the "Company", a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced its operational and financial results for the second quarter ended June 30, 2015. Unless otherwise indicated, all dollar amounts included herein are stated in Canadian dollars.
TRX.VN: 1.120 (-0.030)
Tribute Pharmaceuticals Announces Acquisition of Medical Futures Inc., a Canadian Specialty Pharmaceutical Company
Marketwired - Wed Jun 17, 7:30AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF)(TSX VENTURE: TRX) ("Tribute" or the "Company", a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., is pleased to announce that it has acquired Medical Futures Inc. ("MFI" in a transaction valued at $25 million. Financial terms of the deal include the payment of: $8.3 million in cash on closing; $5 million through the issuance of 3,723,008 common shares in the capital of Tribute; and, $5 million in the form of a one year term promissory note bearing interest at 8% annually convertible at MFI's option at any time during the term into 2,813,778 common shares of Tribute; and future contingent cash milestone payments totaling $6 million based on attainment of certain conditions expected shortly after the close of this transaction. Net Sales of MFI in the twelve month period ended March 31, 2015 were approximately $10 million. This transaction is expected to be immediately accretive. Unless otherwise indicated herein, all references to monetary amounts are in Canadian dollars.
TRX.VN: 1.120 (-0.030)
Pozen buys Tribute Pharma for $146M; both stocks rally
Seeking Alpha - at Seeking Alpha - Mon Jun 08, 11:12AM CDT
POZN: 6.29 (+0.10)
QLT Announces Multiple Transactions Designed to Transform the Company and Create Significant Near- and Long-Term Value for Shareholders
Business Wire - Mon Jun 08, 9:49AM CDT
--Combined Company Will Be Well-Capitalized with a Cash Balance of Approximately $70 Million, Including Newly Invested Capital from Broadfin Capital, JW Asset Management and EcoR1 Capital
QLTI: 3.02 (-0.04), QLT.TO: 3.94 (-0.06), POZN: 6.29 (+0.10)
POZEN Announces Strategic Acquisition of Tribute and Growth Capital Commitment from Leading Healthcare Sponsors
Marketwired - Mon Jun 08, 9:47AM CDT
POZEN Inc. ("POZEN" (NASDAQ: POZN), a pharmaceutical company committed to developing medicine that transforms lives, today announced the acquisition of Tribute Pharmaceuticals Canada Inc. ("Tribute" (TSX VENTURE: TRX)(OTCQX: TBUFF), a Canadian specialty pharmaceutical company, in a transaction valued at approximately US$146 million. Upon completion of the acquisition, which is expected to occur in the fourth quarter of 2015, the combined company will be named Aralez Pharmaceuticals plc ("Aralez" or the "Company" and domiciled in Ireland. Upon closing, Aralez is expected to trade on NASDAQ and TSX.
TRX.VN: 1.120 (-0.030), POZN: 6.29 (+0.10)
Select Sands Announces Arnold Tenney Chairman of the Board
Marketwired - Fri Jun 05, 7:31AM CDT
Select Sands Corp (TSX VENTURE: SNS)(OTC PINK: CLICF) (the "Company" is pleased to announce the appointment of Arnold Tenney as a Chairman of the Board of Directors.
TRX.VN: 1.120 (-0.030), SNS.VN: 0.330 (+0.025)
Tribute Pharmaceuticals Announces Acquisition of U.S. Rights to Fibricor(R) and Commercial Expansion into U.S. Market
Marketwired - Thu May 21, 2:10PM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF)(TSX VENTURE: TRX) ("Tribute" or the "Company", a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., is pleased to announce that its wholly owned subsidiary, Tribute Pharmaceuticals International Inc., a Barbados corporation, has acquired the U.S. rights to Fibricor(R) and its related authorized generic (the "Product" from a wholly owned step-down subsidiary of Sun Pharmaceutical Industries Ltd. ("Sun Pharma". Financial terms of the deal include the payment of US$10 million as follows: US$5 million on closing; US$2 million payable 6 months from closing; and, US$3 million payable 12 months from closing. Sales of the Product during the twelve month period ending April 30, 2015 were approximately US$4.7 million.
TRX.VN: 1.120 (-0.030)
Tribute Pharmaceuticals Canada's (TBUFF) CEO Robert Harris on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue May 12, 11:54AM CDT
Tribute Pharmaceuticals Announces First Quarter 2015 Results
Marketwired - Tue May 12, 6:30AM CDT
Tribute Pharmaceuticals Canada Inc. (TSX VENTURE: TRX)(OTCQX: TBUFF) ("Tribute" or the "Company", a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced its operational and financial results for the first quarter ended March 31, 2015. Unless otherwise indicated, all dollar amounts included herein are stated in Canadian dollars.
TRX.VN: 1.120 (-0.030)
Tribute Pharmaceuticals Schedules First Quarter 2015 Financial Results Conference Call
Marketwired - Fri May 08, 6:28AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF)(TSX VENTURE: TRX) ("Tribute" or the "Company", a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that it will host a conference call on Tuesday, May 12, 2015 at 9:00 AM EDT to review and discuss the Company's results for its first quarter ending March 31, 2015.
TRX.VN: 1.120 (-0.030)
Tribute Pharmaceuticals to Present at the Bloom Burton & Co. Annual Healthcare Investor Conference
Marketwired - Mon Apr 27, 7:54AM CDT
Tribute Pharmaceuticals Canada Inc. (TSX VENTURE: TRX)(OTCQX: TBUFF) ("Tribute" or the "Company", a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that Rob Harris, Chief Executive Officer, will present at the 2015 Bloom Burton & Co. Healthcare Investor Conference at the Sheraton Centre Toronto Hotel on Monday, May 4, 2015, at 2:00 p.m. ET.
TRX.VN: 1.120 (-0.030)
Tribute Comments on Trading Activity at the Request of IIROC
Marketwired - Tue Sep 29, 2:17PM CDT
Tribute Pharmaceuticals Canada Inc. (TSX VENTURE: TRX)(OTCQX: TBUFF) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced at the request of the Investment Industry Regulatory Organization of Canada ("IIROC", that it is not aware of any reason for the recent decrease in the Company's share price. TRX.VN: 1.120 (-0.030), POZN: 6.29 (+0.10)
Tribute Pharmaceuticals posts 2Q loss
Automated Insights - Mon Aug 17, 8:13AM CDT
MILTON, Ontario (AP) _ Tribute Pharmaceuticals Canada Inc. (TBUFF) on Monday reported a loss of $7.2 million in its second quarter.
Tribute Pharmaceuticals Announces Second Quarter 2015 Results
Marketwired - Mon Aug 17, 7:31AM CDT
Tribute Pharmaceuticals Canada Inc. (TSX VENTURE: TRX)(OTCQX: TBUFF) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced its operational and financial results for the second quarter ended June 30, 2015. Unless otherwise indicated, all dollar amounts included herein are stated in Canadian dollars. TRX.VN: 1.120 (-0.030)
Tribute Pharmaceuticals Announces Acquisition of Medical Futures Inc., a Canadian Specialty Pharmaceutical Company
Marketwired - Wed Jun 17, 7:30AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF)(TSX VENTURE: TRX) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., is pleased to announce that it has acquired Medical Futures Inc. ("MFI" in a transaction valued at $25 million. Financial terms of the deal include the payment of: $8.3 million in cash on closing; $5 million through the issuance of 3,723,008 common shares in the capital of Tribute; and, $5 million in the form of a one year term promissory note bearing interest at 8% annually convertible at MFI's option at any time during the term into 2,813,778 common shares of Tribute; and future contingent cash milestone payments totaling $6 million based on attainment of certain conditions expected shortly after the close of this transaction. Net Sales of MFI in the twelve month period ended March 31, 2015 were approximately $10 million. This transaction is expected to be immediately accretive. Unless otherwise indicated herein, all references to monetary amounts are in Canadian dollars. TRX.VN: 1.120 (-0.030)
Pozen buys Tribute Pharma for $146M; both stocks rally
Seeking Alpha - at Seeking Alpha - Mon Jun 08, 11:12AM CDT
POZN: 6.29 (+0.10)
QLT Announces Multiple Transactions Designed to Transform the Company and Create Significant Near- and Long-Term Value for Shareholders
Business Wire - Mon Jun 08, 9:49AM CDT
--Combined Company Will Be Well-Capitalized with a Cash Balance of Approximately $70 Million, Including Newly Invested Capital from Broadfin Capital, JW Asset Management and EcoR1 Capital
QLTI: 3.02 (-0.04), QLT.TO: 3.94 (-0.06), POZN: 6.29 (+0.10)
POZEN Announces Strategic Acquisition of Tribute and Growth Capital Commitment from Leading Healthcare Sponsors
Marketwired - Mon Jun 08, 9:47AM CDT
POZEN Inc. ("POZEN"
(NASDAQ: POZN), a pharmaceutical company committed to developing medicine that transforms lives, today announced the acquisition of Tribute Pharmaceuticals Canada Inc. ("Tribute" (TSX VENTURE: TRX)(OTCQX: TBUFF), a Canadian specialty pharmaceutical company, in a transaction valued at approximately US$146 million. Upon completion of the acquisition, which is expected to occur in the fourth quarter of 2015, the combined company will be named Aralez Pharmaceuticals plc ("Aralez" or the "Company" and domiciled in Ireland. Upon closing, Aralez is expected to trade on NASDAQ and TSX. TRX.VN: 1.120 (-0.030), POZN: 6.29 (+0.10)
Select Sands Announces Arnold Tenney Chairman of the Board
Marketwired - Fri Jun 05, 7:31AM CDT
Select Sands Corp (TSX VENTURE: SNS)(OTC PINK: CLICF) (the "Company"
is pleased to announce the appointment of Arnold Tenney as a Chairman of the Board of Directors. TRX.VN: 1.120 (-0.030), SNS.VN: 0.330 (+0.025)
Tribute Pharmaceuticals Announces Acquisition of U.S. Rights to Fibricor(R) and Commercial Expansion into U.S. Market
Marketwired - Thu May 21, 2:10PM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF)(TSX VENTURE: TRX) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., is pleased to announce that its wholly owned subsidiary, Tribute Pharmaceuticals International Inc., a Barbados corporation, has acquired the U.S. rights to Fibricor(R) and its related authorized generic (the "Product" from a wholly owned step-down subsidiary of Sun Pharmaceutical Industries Ltd. ("Sun Pharma". Financial terms of the deal include the payment of US$10 million as follows: US$5 million on closing; US$2 million payable 6 months from closing; and, US$3 million payable 12 months from closing. Sales of the Product during the twelve month period ending April 30, 2015 were approximately US$4.7 million. TRX.VN: 1.120 (-0.030)
Tribute Pharmaceuticals Canada's (TBUFF) CEO Robert Harris on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue May 12, 11:54AM CDT
Tribute Pharmaceuticals Announces First Quarter 2015 Results
Marketwired - Tue May 12, 6:30AM CDT
Tribute Pharmaceuticals Canada Inc. (TSX VENTURE: TRX)(OTCQX: TBUFF) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced its operational and financial results for the first quarter ended March 31, 2015. Unless otherwise indicated, all dollar amounts included herein are stated in Canadian dollars. TRX.VN: 1.120 (-0.030)
Tribute Pharmaceuticals Schedules First Quarter 2015 Financial Results Conference Call
Marketwired - Fri May 08, 6:28AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF)(TSX VENTURE: TRX) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that it will host a conference call on Tuesday, May 12, 2015 at 9:00 AM EDT to review and discuss the Company's results for its first quarter ending March 31, 2015. TRX.VN: 1.120 (-0.030)
Tribute Pharmaceuticals to Present at the Bloom Burton & Co. Annual Healthcare Investor Conference
Marketwired - Mon Apr 27, 7:54AM CDT
Tribute Pharmaceuticals Canada Inc. (TSX VENTURE: TRX)(OTCQX: TBUFF) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that Rob Harris, Chief Executive Officer, will present at the 2015 Bloom Burton & Co. Healthcare Investor Conference at the Sheraton Centre Toronto Hotel on Monday, May 4, 2015, at 2:00 p.m. ET. TRX.VN: 1.120 (-0.030)
(0)
(0)